Deletion of the Long Arm of Chromosome 20 (20q-) Is a Recurrent Genetic Marker in Acute Erythroid Leukemia.
Rebecca M Ziegler, Lori Failla, Frederick K Racke, Weiqiang Zhao. The Ohio State University, Columbus
Background: The deletion of 20q11.2-11.3 (20q-) was a well-recognized chromosomal anomaly in hematopoietic disorders such as polycythemia vera, myelodysplastic syndrome (MDS), and acute myeloid leukemia (AML). We investigated if 20q- is a recurrent marker for acute erythroid leukemia (M6a) using clinicopathologic correlation.
Design: AML M6a patients with or without 20q- evaluated at our institution were compiled and analyzed for basic CBC, bone marrow, cytogenetic, and clinical survival features using Student t-test or Fisher exact probability test (F-test). The findings were considered to be statistically significant if p<0.05.
Results: From 1079 patients diagnosed with either AML (736) or MDS (340), 2.0% (22/1079) of cases had 20q-. Among 736 AML, 26 were M6a. Six (23%) M6a had 20q-, but only 1 (0.14%) of the non M6a AML had 20q-. Therefore, 20q- was more commonly found in M6a than other types of AML (p<0.001, Odds Ratio=44.8; 95% IC: 24.5-81.7). No differences were observed between M6a with or without 20q- in regards to patient age, gender, hemoglobin, WBC, and platelet counts. Compared to the remaining M6a without 20q-, M6a with 20q- patients were more likely to have lower blast counts (11% vs. 18%) (p=0.0237), but had more erythroid precursors (67% vs. 57%, p=0.05) in a bone marrow with similar cellularity (55% vs. 68%, p=0.17) when compared to M6a without 20q-. The median survival time for M6a with 20q- was slightly shorter than M6a without 20q- (3 vs. 5 mo, p=0.22).
Conclusions: Our study revealed that 20q- was more commonly found in M6a than any other type of AML, but the presence of this abnormality appears to have little impact on the clinical outcomes when compared to M6a without this genomic abnormality.
Monday, February 28, 2011 1:00 PM
Poster Session II # 171, Monday Afternoon